Antitrust

02/03/2014

Pay-For-Delay Pharmaceutical Litigation

Pay For Delay Drug Litigation

In recent years, increasing scrutiny has been given to the practice of pharmaceutical manufacturers seeking to suppress the introduction of less expensive generic drugs into the market by artificial and potentially illegal means.  In some instances, the manufacturers of brand-name drugs will enter into anti-competitive  agreements with generic drug manufacturers pursuant to which the generic drugs will be withheld from the market for a predetermined amount of time.  Employing another tactic, the brand-name manufacturer may engage in sham patent litigation... Read More
04/19/2013

Stericycle, Inc. Excessive Billing

stericycle_excessive_charges

Stericycle, Inc., a publicly-traded company with revenue swelling 14.1% in 2012 to $1.96 billion, maintains an expansive network of medical waste transport vehicles, collection sites, and treatment facilities in the United States and 11 international markets.  Stericycle's extensive customer base includes hospitals, laboratories, physician practices, dental offices, long-term care facilities, blood banks, veterinarians, and other generators of biohazardous waste. Following the enactment of the Medical Waste Tracking Act of 1988, Stericycle was formed in 1989.  Since becoming a publicly-traded company in... Read More